Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Summary
This is a randomized, open-label, multicenter, phase 3 clinical study comparing the efficacy and safety of SHR-A1811 in combination with Adebrelimab versus platinum-based doublet chemotherapy in combination with Tislelizumab as first-line treatment in patients with HER2-overexpressing locally advanced or metastatic non-squamous non-small cell lung cancer.
Official title: A Randomized, Controlled, Open-label, Multicenter Phase III Study of SHR-A1811 Combined With Adebrelimab for the First-line Treatment of Patients With HER2-overexpressing Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
436
Start Date
2026-12
Completion Date
2032-03
Last Updated
2026-10-26
Healthy Volunteers
No
Conditions
Interventions
SHR-A1811 Injection
SHR-A1811 Injection.
Adebrelimab Injection
Adebrelimab Injection.
Tislelizumab Injection
Tislelizumab Injection.
Pemetrexed Disodium For Injection
Pemetrexed Disodium For Injection.
Carboplatin injection
Carboplatin Injection.
Cisplatin injection
Cisplatin Injection.
Locations (2)
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China